Reporting Another Profitable Year, Genomic Health Considers Prostate Cancer Dx Next Big Opportunity
February 08, 2012
Reporting Another Profitable Year, Genomic Health Considers Prostate Cancer Dx Next Big Opportunity
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genomic Health Partners with OncoMed to Grow Companion Dx, NGS Reach
May 9, 2012 / Pharmacogenomics Reporter - After 14 Percent Revenue Bump in 2012, Genomic Health Focusing on Market Growth, Prostate Dx Launch
February 13, 2013 / Pharmacogenomics Reporter - Spinning out InVitae, Genomic Health Aims to Maintain Core Focus on Cancer Diagnostics
August 15, 2012 / Pharmacogenomics Reporter - Genomic Health Updates Analysts on Companion Dx Pipeline, New Education Campaign
November 10, 2010 / Pharmacogenomics Reporter - With 8 Percent Revenue Bump in Q1, Genomic Health Focus on Expanding Oncotype DX Franchise
May 8, 2013 / Pharmacogenomics Reporter